|
1
|
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
|
Cancer Res
|
2011
|
2.13
|
|
2
|
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
|
Mol Pharmacol
|
2013
|
1.23
|
|
3
|
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.
|
Cancer Biol Ther
|
2012
|
1.12
|
|
4
|
Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.
|
Mol Pharmacol
|
2012
|
1.10
|
|
5
|
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
|
Cancer Biol Ther
|
2013
|
1.05
|
|
6
|
PDE5 inhibitors enhance celecoxib killing in multiple tumor types.
|
J Cell Physiol
|
2015
|
0.99
|
|
7
|
Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells.
|
Mol Pharmacol
|
2013
|
0.95
|
|
8
|
A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.
|
Mol Pharmacol
|
2010
|
0.94
|
|
9
|
Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells.
|
Cancer Biol Ther
|
2013
|
0.92
|
|
10
|
Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma.
|
Brain Res
|
2007
|
0.89
|
|
11
|
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.
|
Cancer Biol Ther
|
2014
|
0.88
|
|
12
|
OSU-03012 interacts with lapatinib to kill brain cancer cells.
|
Cancer Biol Ther
|
2012
|
0.88
|
|
13
|
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
|
Autophagy
|
2011
|
0.86
|
|
14
|
Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
|
Cancer Biol Ther
|
2011
|
0.84
|
|
15
|
Can the lack of HSP90alpha protein in brain normal tissue and cell lines, rationalise it as a possible therapeutic target for gliomas?
|
Cancer Invest
|
2008
|
0.81
|